lunes, 25 de diciembre de 2017

Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers. - PubMed - NCBI

2017 Dec 15;12(12):e0189641. doi: 10.1371/journal.pone.0189641. eCollection 2017.

Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers.

Gschwantler-Kaulich D1, Weingartshofer S1, Rappaport-Fürhauser C1, Zeilinger R1, Pils D2,3, Muhr D1, Braicu EI4, Kastner MT1, Tan YY1,5, Semmler L1, Sehouli J4, Singer CF1.

Author information

Abstract

BACKGROUND:

Screening for ovarian cancer (OC) in women at high risk consists of a combination of carbohydrate antigen 125 (CA125) and transvaginal ultrasound, despite their low sensitivity and specificity. This could be improved by the combination of several biomarkers, which has been shown in average risk patients but has not been investigated until now in female BRCA mutation carriers.

METHODS:

Using a multiplex, bead-based, immunoassay system, we analyzed the concentrations of leptin, prolactin, osteopontin, insulin-like growth factor II, macrophage inhibitory factor, CA125 and human epididymis antigen 4 in 26 healthy wild type women, 26 healthy BRCA1 mutation carriers, 28 wildtype OC patients and 26 OC patients with BRCA1 mutation.

RESULTS:

Using the ROC analysis, we found a high overall sensitivity of 94.3% in differentiating healthy controls from OC patients with comparable results in the wildtype subgroup (sensitivity 92.8%, AUC = 0.988; p = 5.2e-14) as well as in BRCA1 mutation carriers (sensitivity 95.2%, AUC = 0.978; p = 1.7e-15) at an overall specificity of 92.3%. The used algorithm also allowed to identify healthy BRCA1 mutation carriers when compared to healthy wildtype women (sensitivity 88.4%, specificity 80.7%, AUC = 0.895; p = 6e-08), while this was less pronounced in patients with OC (sensitivity 66.7%, specificity 67.8%, AUC = 0.724; p = 0.00065).

CONCLUSION:

We have developed an algorithm, which can differentiate between healthy women and OC patients and have for the first time shown, that such an algorithm can also be used in BRCA mutation carriers. To clarify a suggested benefit to the existing early detection program, large prospective trials with mainly early stage OC cases are warranted.